Search clinical trials for: Subcutaneous octreotide acetate

Total 4909 results

Azidus Brasil

Suspended

Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®

Acromegaly

Brazil
Camurus AB

Active, not recruiting

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Acromegaly

United States, Spain, United Kingdom, Germany, Russian Federation, Greece, Hungary, Italy, Poland, Turkey, Serbia
Novartis

Completed

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

Diabetic Retinopathy

United States
Dauntless Pharmaceuticals

Completed

Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers

Healthy Volunteer Study

United States
Camurus AB

Active, not recruiting

A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD (POSITANO)

Polycystic Liver Disease

United States, Germany, Belgium, Netherlands
Camurus AB

Completed

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (ACROINNOVA 1)

Acromegaly

United States, Spain, United Kingdom, Germany, Russian Federation, Greece, Hungary, Italy, Poland, Turkey
Endo Pharmaceuticals

Completed

Open Label Study of Octreotide Implant in Patients With Acromegaly

Acromegaly
Novartis Pharmaceuticals

Terminated

Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas

Acromegaly

Mexico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Octreotide in Treating Patients With Cancer-Related Malignant Ascites

Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer

United States
University College, London
National Institute for Health Research, United Kingdom

Active, not recruiting

A Feasibility Study of Octreotide Infusion During Liver Transplant. (Octreotide)

Liver Transplantation | Renal Failure

United Kingdom
Lexicon Pharmaceuticals

Completed

Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects

Drug Interactions

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

Colorectal Cancer | Anal Cancer | Drug/Agent Toxicity by Tissue/Organ | Radiation Enteritis

United States
Novartis Pharmaceuticals

Terminated

Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

Diabetic Retinopathy
Debiopharm International SA

Active, not recruiting

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01)

Acromegaly | GEP-NET

United Kingdom, France, Spain, Italy, Poland, Denmark, Germany, Israel
Novartis Pharmaceuticals

Terminated

Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

Diabetic Retinopathy
Novartis Pharmaceuticals

Completed

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Acromegaly

Germany
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Head and Neck Cancer | Metastatic Cancer | Pheochromocytoma | Islet Cell Tumor

United States
University Health Network, Toronto

Unknown

Fecal Calprotectin Levels in Mycophenolate Mofetil Induced Diarrhea and Treatment With Octreotide

Diarrhea | Immunosuppression

Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis

Sarcoma | Cervical Cancer | Diarrhea | Colorectal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Vulvar Cancer | Endometrial Cancer | Vaginal Cancer
Northwestern University
National Cancer Institute (NCI)

Completed

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Small Intestine Cancer | Ovarian Cancer | Peritoneal Cavity Cancer | Gastrointestinal Stromal Tumor | Extrahepatic Bile Duct Cancer | Nausea and Vomiting | Constipation, Impaction, and Bowel Obstruction

United States
Asan Medical Center
Novartis Korea Ltd.

Unknown

Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues (acromegaly)

Acromegaly

Korea, Republic of
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Liver Cancer

United States
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients (HOSCAR)

Acromegaly

Italy, France, Portugal, Poland, Switzerland
Novartis

Completed

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

Diabetic Retinopathy

United States
Advanced Accelerator Applications

Completed

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1)

Carcinoid Tumor of the Small Bowel | Neuroendocrine Tumour

United States, United Kingdom, Italy, Belgium, France, Germany, Portugal, Spain
Novartis Pharmaceuticals

Completed

Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly

Acromegaly

Italy
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B; SWOG Cancer Research...

Completed

Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer

Diarrhea | Colorectal Cancer

United States
Sinotau Pharmaceutical Group

Recruiting

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Neuroendocrine Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Single-dose Study of Octreotide Injection in Healthy Adult Subjects

Acromegaly

China
Ambrilia Biopharma, Inc.

Terminated

Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

Acromegaly

United States, Belarus, Hungary, Serbia, Ukraine, Romania
Ambrilia Biopharma, Inc.

Completed

Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

Acromegaly

Belarus, Hungary, Romania, Serbia, Slovakia, Ukraine
St. Josef Hospital Bochum

Completed

Effects of Intraarterial Octreotide on Pancreatic Texture

Pancreatic Fistula

Germany
Stealth BioTherapeutics Inc.

Completed

ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA (ReCLAIM-2)

Age-related Macular Degeneration

United States
National Cancer Institute, Naples

Completed

Octreotide LAR in the Induction of Immunologic Response in NENs Patients (CSMS99)

Neuroendocrine Tumors

Italy
Karolinska Institutet

Completed

Hemodynamic Effects of Cold Versus Warm Fluid Bolus

Temperature Change, Body | Hypovolemia

Sweden
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma

Thymoma and Thymic Carcinoma

United States, South Africa
AdventHealth

Terminated

Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding

Adenoma

United States
Novartis

Terminated

Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

Diarrhea | Colorectal Cancer

United States
Novartis Pharmaceuticals

Completed

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Peritoneal Neoplasms | Intestinal Obstruction | Carcinomatosis

France
Aspireo Pharmaceuticals Limited

Completed

Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173

Healthy
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

Lymphoma

United States, Canada
Jinling Hospital, China

Completed

Autologous Fibrin Glues for Fistulas Closure

Intra-abdominal Infection | Enterocutaneous Fistulas

China
Mayo Clinic

Completed

Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis

Cirrhosis | Portal Hypertension | Esophageal Varices
University of Pittsburgh
National Cancer Institute (NCI)

Completed

Octreotide and Doxorubicin in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Chengfeng Wang

Unknown

The Effect of Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide on the Complications After Pancreatectomy. A Prospective, Multicenter Clinical Trial

Pancreatic Diseases

China
Novartis Pharmaceuticals

Completed

Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea (LARCID)

Chemotherapy-induced Diarrhea

Brazil
Qilu Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Two Octreotide Microsphere Formulations in Healthy Volunteers

Healthy Volunteers

China
Peking University

Unknown

Octreotide LAR as Maintenance Treatment for Patients With NEC

Esophageal Neuroendocrine Carcinoma | Gastro-entero-pancreatic Carcinoma

China
Qilu Hospital of Shandong University

Not yet recruiting

A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors

Neuroendocrine Tumors

China
Teva Takeda Pharma Ltd.

Completed

Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"

Multiple Sclerosis

Japan

Search clinical trials for: Subcutaneous octreotide acetate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations